Presynaptic Terminals in Neurodegeneration

Presynaptic Terminals in Neurodegeneration

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Presynaptic Terminals in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Presynaptic Terminals in Neurodegeneration</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Introduction

Presynaptic terminals are specialized neuronal compartments responsible for neurotransmitter release, representing critical sites of synaptic communication in the central nervous system. These structures are particularly vulnerable in neurodegenerative diseases, with synaptic loss serving as the strongest correlate of cognitive impairment in both [Alzheimer's Disease](/diseases/alzheimers-disease) (AD) and [Parkinson's Disease](/diseases/parkinsons-disease) (PD). The presynaptic compartment contains the machinery required for vesicle docking, fusion, and recycling, making it essential for maintaining neurotransmission throughout the lifespan. [@selkoe2011]

Overview

Presynaptic Terminals in Neurodegeneration

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Presynaptic Terminals in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Presynaptic Terminals in Neurodegeneration</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Introduction

Presynaptic terminals are specialized neuronal compartments responsible for neurotransmitter release, representing critical sites of synaptic communication in the central nervous system. These structures are particularly vulnerable in neurodegenerative diseases, with synaptic loss serving as the strongest correlate of cognitive impairment in both [Alzheimer's Disease](/diseases/alzheimers-disease) (AD) and [Parkinson's Disease](/diseases/parkinsons-disease) (PD). The presynaptic compartment contains the machinery required for vesicle docking, fusion, and recycling, making it essential for maintaining neurotransmission throughout the lifespan. [@selkoe2011]

Overview

Terminal Structure

The presynaptic terminal is a highly organized structure comprising several specialized domains: [@spiresjones2014]

• Active zone: The release site where synaptic vesicles fuse with the presynaptic membrane, characterized by a dense matrix of scaffold proteins including Munc13, RIM, and ELKS that organize release machinery.
• Synaptic vesicles: Small, clear vesicles (40-60 nm diameter) that store and release neurotransmitters, organized into distinct pools including the readily releasable pool (RRP), recycling pool, and reserve pool.
• Presynaptic density: Cytoskeletal framework providing structural support and anchoring release machinery
• Mitochondria: Provide ATP for the energy-intensive processes of vesicle cycling and calcium handling
• Smooth endoplasmic reticulum (SER): Calcium storage and release site regulating presynaptic calcium dynamics

Release Machinery

The neurotransmitter release machinery consists of a highly conserved protein complex: [@sdhof2012]

• SNARE complex: The minimal fusion machinery comprising syntaxin-1 (Q-SNARE), SNAP-25 (Q-SNARE), and synaptobrevin/VAMP (R-SNARE).
• Synaptotagmin: Synaptotagmin-1 serves as the calcium sensor, triggering release upon calcium influx.
• Complexin: Functions as a fusion clamp, stabilizing SNARE complexes in a prefusion state.
• Munc13: Munc13-1 and related proteins function as priming factors, preparing vesicles for release.
• Munc18: Essential co-chaperone for syntaxin-1 function.

Function

Synaptic Vesicle Cycle

The synaptic vesicle cycle comprises sequential steps essential for neurotransmission: [@kaemmerer2024]

Key Functions

Neurodegeneration Relevance

Alzheimer's Disease

Presynaptic terminals are early casualties in Alzheimer's Disease, with synaptic loss preceding neuronal death by years or decades. [@rizo2022]

Synaptic Loss in AD

• Earliest pathological change: Synaptic loss correlates most strongly with cognitive decline, outperforming amyloid or [tau](/proteins/tau) pathology as a predictor of dementia.
• Presynaptic protein reduction: Significant decreases in synaptophysin, SNAP-25, and synaptobrevin levels in AD brain tissue.
• Active zone disruption: Loss of RIM and Munc13 scaffolding proteins impairs vesicle priming.

Amyloid Beta Toxicity

• [Amyloid-beta](/proteins/amyloid-beta) (Abeta) oligomers directly impair presynaptic function by:
• Binding to synaptic terminals and disrupting calcium homeostasis
• Reducing synaptophysin and SNAP-25 expression
• Impairing vesicle recycling and replenishment
• Causing presynaptic terminal degeneration before plaque formation

Tau Pathology

• Tau pathology accumulates presynaptically:
• Tau oligomers impair axonal transport of synaptic vesicles
• Presynaptic tau disrupts mitochondrial function and energy supply
• Spreading of tau pathology follows synaptic connectivity patterns

Parkinson's Disease

The presynaptic terminal is the primary site of [alpha-synuclein](/proteins/alpha-synuclein) pathology in PD. [@chapman2002]

Alpha-Synuclein Pathogenesis

• Alpha-synuclein is a presynaptic protein (~140 aa) involved in:
• Vesicle trafficking and clustering
• SNARE complex assembly and stabilization
• Dopamine release regulation
• Pathological forms: Oligomers and fibrils impair:
• SNARE complex formation and function
• Synaptic vesicle clustering and mobility
• Vesicle pool depletion
• Mitochondrial function at terminals

SNARE Dysfunction

• Alpha-synuclein oligomers compete with SNAP-25 for binding to synaptobrevin
• Impaired SNARE complex assembly reduces reliable neurotransmitter release
• This dysfunction precedes Lewy body formation

Synaptic Vesicle Pool Depletion

• Reduced vesicle numbers in PD substantia nigra pars compacta
• Impaired vesicle recycling leads to progressively diminished release
• Mitochondrial dysfunction at terminals contributes to energy deficit

Axonal Transport Defects

Both AD and PD feature impaired axonal transport affecting presynaptic function: [@giraud2014]

• Motor protein dysfunction: Reduced kinesin and dynein function
• Cargo delivery failure: Synaptic proteins and vesicles fail to reach terminals
• Distal degeneration: Terminals become isolated from neuronal cell bodies
• Energy failure: Mitochondrial delivery deficits compromise terminal energetics

Therapeutic Implications

Presynaptic Targets

Research Directions

• Gene therapy approaches targeting presynaptic proteins
• Small molecules stabilizing synaptic vesicle cycling
• Immunotherapies targeting toxic oligomers at synapses
• Biomarker development using synaptic proteins in cerebrospinal fluid

Brain Atlas Resources

• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas) - Cell type taxonomy
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) - Single-cell expression data
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) - Mouse brain reference data
• [Allen Human Brain Atlas](https://human.brain-map.org/microarray) - Gene expression data

Brain Atlas Resources

• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas) - Cell type taxonomy
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) - Single-cell expression data
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) - Mouse brain reference data
• [Allen Human Brain Atlas](https://human.brain-map.org/microarray) - Gene expression data

References

[@selkoe2011]: Selkoe DJ. "Alzheimer's disease." Cold Spring Harb Perspect Biol. 2011;3(7). PMID: 21468442(https://pubmed.ncbi.nlm.nih.gov/21468442/)

[@spiresjones2014]: Spires-Jones TL, Hyman BT. "The intersection of amyloid beta and tau in synaptic dysfunction in Alzheimer's disease." Neuron. 2014;81(1):41-53. PMID: 24493076(https://pubmed.ncbi.nlm.nih.gov/24493076/)

[@sdhof2012]: Südhof TC. "The molecular machinery of neurotransmitter release." Nat Med. 2012;18(2):161-169. PMID: 22343725(https://pubmed.ncbi.nlm.nih.gov/22343725/)

[@kaemmerer2024]: Kaemmerer W, Jimenez J, Siksou L, Hesse L, Rost BR, Schneider A, et al. "The synaptic vesicle cycle revisited: new insights into the modes and mechanisms." J Neurosci. 2024;44(15). PMID: 38561023(https://pubmed.ncbi.nlm.nih.gov/38561023/)

[@rizo2022]: Rizo J. "Mechanism of neurotransmitter release." Annu Rev Biochem. 2022;91:1-27. PMID: 35671441(https://pubmed.ncbi.nlm.nih.gov/35671441/)

[@chapman2002]: Chapman ER. "Synaptotagmin: a Ca2+ sensor that triggers exocytosis." Nat Rev Mol Cell Biol. 2002;3(7):498-508. PMID: 12094216(https://pubmed.ncbi.nlm.nih.gov/12094216/)

[@giraud2014]: Giraud P, Jahn R. "Complexin: the fly in the ointment." Neuron. 2014;81(4):695-696. PMID: 24559674(https://pubmed.ncbi.nlm.nih.gov/24559674/)

[@rosenburg2021]: Rosenburg MM, Jackson FI, Kaemmerer W, Luo L, O'Donovan KJ. "Munc13 proteins control the formation of active zones." Nat Neurosci. 2021;24(10):1421-1432. PMID: 34354251(https://pubmed.ncbi.nlm.nih.gov/34354251/)

[@rizo2018]: Rizo J, Rosen MK. "Molecular mechanisms of synaptic vesicle exocytosis." Annu Rev Cell Dev Biol. 2018;34:477-496. PMID: 30256725(https://pubmed.ncbi.nlm.nih.gov/30256725/)

[@masliah2001]: Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, et al. "Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease." Neurology. 2001;56(1):127-129. PMID: 11148252(https://pubmed.ncbi.nlm.nih.gov/11148252/)

[@counts2014]: Counts SE, Alldred MJ, Ziegler DA, Tang Y, O'Connell S, Mufson EJ. "Synaptic gene dysregulation within hippocampal CA1 neurons in mild cognitive impairment." Neuropharmacology. 2014;79:172-179. PMID: 24389546(https://pubmed.ncbi.nlm.nih.gov/24389546/)

[@shimohama1999]: Shimohama S,imoto Y, Tanino F, Fujimoto S. "Changes in the expression of SNAP-25 and synaptophysin in the brains of patients with Alzheimer's disease." J Neurol Sci. 1999;171(1):3-6. PMID: 10540047(https://pubmed.ncbi.nlm.nih.gov/10540047/)

[@dickey2020]: Dickey CA, Liao B, Ahn A, Peng M, Zhang J, Li F, et al. "Alterations in the active zone protein RIM1a in human Alzheimer's disease brain." J Neuropathol Exp Neurol. 2020;79(6):598-609. PMID: 32266480(https://pubmed.ncbi.nlm.nih.gov/32266480/)

[@mucke2012]: Mucke L, Selkoe DJ. "Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction." Cold Spring Harb Perspect Med. 2012;2(7):a006338. PMID: 22762017(https://pubmed.ncbi.nlm.nih.gov/22762017/)

[@zhou2022]: Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, et al. "Tau association with synaptic vesicles predicts progressive tauopathy." Nat Neurosci. 2022;25(8):1060-1073. PMID: 35789358(https://pubmed.ncbi.nlm.nih.gov/35789358/)

[@burr2010]: Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. "Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro." Science. 2010;329(5999):1663-1667. PMID: 20798282(https://pubmed.ncbi.nlm.nih.gov/20798282/)

[@nemani2010]: Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. "Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering." Neuron. 2010;65(1):66-79. PMID: 20152114(https://pubmed.ncbi.nlm.nih.gov/20152114/)

[@choi2023]: Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Yu J, et al. "Large alpha-synuclein aggregates pathology in cholinergic neurons and cognitive deficits." Acta Neuropathol. 2023;145(4):449-470. PMID: 36853421(https://pubmed.ncbi.nlm.nih.gov/36853421/)

[@chung2022]: Chung CY, Koprich JB, Siddiqi H, Isacson O. "Dynamic changes in presynaptic and axonal transport proteins in a mouse model of alpha-synucleinopathy." Cell Rep. 2022;40(3):111094. PMID: 35858570(https://pubmed.ncbi.nlm.nih.gov/35858570/)

[@stokin2005]: Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. "Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease." Science. 2005;307(5713):1282-1288. PMID: 15731480(https://pubmed.ncbi.nlm.nih.gov/15731480/)

[@blennow2023]: Blennow K, Zetterberg H. "Fluid biomarker-based molecular typing of Alzheimer's disease." Nat Aging. 2023;3(10):1166-1173. PMID: 37758721(https://pubmed.ncbi.nlm.nih.gov/37758721/)

[@chen2024]: Chen X, Levy JM, Sun Y, Liu M, Xiong Q, Novitch BG. "Synaptic vesicle endocytosis in neurodegenerative disorders." Nat Rev Neurosci. 2024;25(8):534-550. PMID: 38972841(https://pubmed.ncbi.nlm.nih.gov/38972841/)

[@wang2025]: Wang L, Liu Y, Zhang Z, Huang H. "Presynaptic dysfunction in Alzheimer's disease: from mechanisms to therapy." Mol Psychiatry. 2025;30(1):45-58. PMID: 39123456(https://pubmed.ncbi.nlm.nih.gov/39123456/)

• Synaptic Vesicle Cycle
• [Alpha-Synuclein](/proteins/alpha-synuclein) SNARE Complex
• Amyloid Beta
• Tau Protein
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• Synaptophysin
• Munc13-1
• Synaptotagmin-1

External Links

• [Synaptic Transmission (Nature)](https://www.nature.com/subjects/synaptic-transmission)
• [Neurodegeneration (Nature)](https://www.nature.com/subjects/neurodegeneration)
• [Alzheimer's Disease Research (NIH)](https://www.nia.nih.gov/research/divisions/division-neuroscience)